Neuble AI

Name: Neuble AI
Brand: Neuble AI

Neuble AI is a medical imaging AI company that derives MRI-like quantitative brain measurements from CT scans by applying segmentation, registration, and image-processing workflows to produce regional volumetry and automated reports.

3 Ref Customers

Website

Published Sep 3, 2026

01Common complaints

- If you need established third-party validation and abundant peer reviews - Neuble currently shows limited presence on major review platforms under its name; buyers who rely on extensive independent reviews may prefer vendors with broader third-party coverage. - If your use case requires MRI-native biomarkers and protocol-specific outputs - For advanced neurodegenerative biomarkers where MRI sequences (T1/T2/FLAIR, etc.) are central, MRI-first tools may be more appropriate. - If you require clear, publicly documented security/compliance posture up front - Without published SOC 2/ISO/HIPAA/GDPR statements, highly regulated health systems may block procurement early. - If regulatory clearance is mandatory for your intended use today - Funding coverage indicates regulatory submissions are a stated goal; until specific approvals/clearances are confirmed for your geography and intended use, alternatives with documented clearances may present lower regulatory risk. - Publicly acknowledged limitations - No explicit limitations or failure-mode documentation was found on Neuble’s public pages accessed (e.g., known failure modes, contraindicated scan protocols, or quality thresholds). - Likely limitations buyers should test during evaluation (practical) - Performance variance by: - CT acquisition parameters (slice thickness, reconstruction kernel) - Scanner vendor/model differences - Presence of artifacts (motion, metal) - Post-surgical changes - QC requirements: - Need for visual overlays and human review to detect segmentation failures - Clinical interpretability: - How volumetry outputs map to actionable clinical decisions versus metrics that are primarily of research interest - Roadmap signals - Neuble indicates future lineup expansion to AngioCura (vascular analysis) and ReadCura (reading assistance), and third-party coverage mentions SynCura (CT-to-MRI synthesis).

Deal disqualifiers (poor fit)

Clinical questions that truly require MRI tissue contrast (e.g., subtle lesion characterization) where CT-derived metrics are insufficient
Organizations requiring formal, published security attestations prior to pilot may find the vendor's public documentation inadequate

02Why they buy

- Vendor-stated differentiators - The company describes its approach as producing MRI-like insights from CT scans. - BrainCura is reported by the vendor to perform CT-only segmentation into 98 brain regions and to generate volumetric reporting. - The vendor reports a DSC performance value (0.92) for major structures in its evaluations. - Limitations of available evidence - Independence: performance claims appear primarily in vendor-published materials; limited independent, multi-site published validations were found. - Commercial proof: limited public customer logos, named case studies, or platform reviews were identified in the sources reviewed. - Where competitors may have clearer product signals - Some competitors publicly disclose deployment requirements and regulatory achievements, which can signal greater product maturity in certain markets or use cases.

03Field reports

Reality check on review availability

Neuble AI does not appear to have meaningful coverage on mainstream B2B review platforms (G2, TrustRadius, Gartner Peer Insights) under the “Neuble AI” name in accessible searches. Searches surfaced similarly named but unrelated products.
As a result, no credible end-user star ratings or large-scale review corpuses were found for Neuble itself.

Community/social signal (Reddit, HackerNews)

No high-signal Reddit threads or HackerNews discussions specifically about Neuble AI / BrainCura were found in the searches performed.

Vendor/academic-adjacent statements (not customer reviews, but useful sentiment/claims)

- Neuble’s official materials report that BrainCura achieves a high Dice similarity coefficient for major brain structure segmentation and positions its performance as comparable to MRI-based products in some internal/external validations (vendor-published claims). - A research preprint (“HippoCura”) related to CT hippocampal segmentation includes author affiliations/conflicts indicating Neuble AI leadership/research involvement, suggesting active R&D but not equivalent to documented customer satisfaction.

What this means for buyers

For a procurement decision, buyers will likely need:
- Reference calls with pilot sites
- Peer-reviewed validation (ideally independent)
- Clear regulatory status by geography (relevant regulators such as MFDS / FDA / CE)

Public case studies

No detailed official case studies (e.g., named healthcare institutions, measured clinical outcomes, or time-to-value data) were found in the accessed Neuble AI sources.

Vendor-published performance claims (not independently verified)

- Vendor statements include: - CT-only segmentation into numerous brain regions - A very high Dice similarity coefficient reported for key structures (vendor-reported) - Reporting capabilities for brain atrophy patterns, CT-based brain age, and Alzheimer’s monitoring - Critical evaluation - These are vendor statements without accessible, independently audited methodology in the sources reviewed. - A reported DSC value can be meaningful but is sensitive to: - Which structures are evaluated - Ground truth creation process (especially if CT labels are derived from MRI registrations) - Dataset composition and site diversity

Related external technical evidence (adjacent, not Neuble-specific)

Academic literature supports that deep learning segmentation on CT is feasible but challenging; performance can vary significantly by anatomy and data variability.
The HippoCura preprint describes CT-to-MRI alignment and reports acceptability metrics; however, the authors include Neuble AI-affiliated researchers, which limits independence.

04Best fit

Company sizes

Likely best fit: mid-size to large hospital systems and imaging networks with neuro service lines, plus regional hospitals that lack sufficient MRI capacity.
Research hospitals running neurodegenerative disease programs that seek CT-based adjunct measures.

Industries and verticals

Hospitals and health systems
Diagnostic imaging centers
Neuro clinics affiliated with hospitals (if integrated with imaging)

Roles and personas

Decision makers:
- Radiology leadership
- Neurology leadership (memory clinics)
- CIO/CTO, PACS administrators
- Clinical engineering / vendor management / procurement
End users:
- Radiologists
- Neurologists
- Imaging technologists (workflow)

Pain points addressed

MRI access bottlenecks (wait times) and cost barriers
Need for quantitative monitoring (atrophy/volumetry) when MRI is not available for every assessment

Qualification criteria (good fit)

High CT volume with constrained MRI access
Strong IT integration capability (PACS/DICOM routing)
Ability to run pilots and track outcomes

05The pitch

What the product does (core value proposition in objective terms)

- Neuble AI is a medical imaging AI company that develops algorithms to derive MRI-like brain measurements from CT scans. The company uses CT as the acquisition modality and applies image processing, registration, and segmentation to estimate quantitative brain information commonly derived from MRI workflows. - The primary product, BrainCura, is described by the vendor as performing detailed regional segmentation from CT and producing volumetric measurements and reports intended to support assessment and monitoring of neurodegenerative conditions.

Target market and market positioning

Target buyers appear to be hospitals, imaging centers, and neurology/radiology workflows where MRI access is constrained (long waits, contraindications, cost).
The company emphasizes accessibility and throughput by using CT to approximate higher-fidelity brain analytics that are typically obtained from MRI.

Get a comprehensive analysis of Neuble AI including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →